METTL16 and breast cancer: When YTHDC1 is downregulated, PTEN expression decreases, leading to enhanced AKT signaling, higher cell survival rates, and increased cisplatin resistance.43 Besides, METTL16 influences the sensitivity of BC cells to cisplatin by regulating autophagy-related pathways through m6A modification of PMEPA1 mRNA.17